Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Huizing, A. Keung, H. Rosing, V. Kuij, W. Huinink, I. Mandjes, A. Dubbelman, H. Pinedo, J. Beijnen (1993)
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 11
E. Rowinsky, M. Gilbert, W. McGuire, D. Noe, L. Grochow, A. Forastiere, D. Ettinger, B. Lubejko, B. Clark, S. Sartorius (1991)
Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 9
R. Motzer, D. Bajorin, L. Schwartz, H. Hutter, G. Bosl, H. Scher, P. Lyn, P. Fischer (1994)
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 11
C. Hudis, A. Seidman, J. Crown, C. Balmaceda, R. Freilich, T. Gilewski, T. Hakes, V. Currie, D. Lebwohl, J. Baselga, G. Raptis, M. Gollub, M. Robles, R. Bruno, L. Norton (1996)
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 1
A. Einzig, D. Neuberg, S. Remick, D. Karp, P. O'dwyer, J. Stewart, A. Benson (1996)
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293Medical Oncology, 13
T. Berghmans, J. Sculier, D. Valeriola, J. Klastersky (1994)
Phase I study of Amphotericin B lipid complex with ABLC pharmacokinetics in patients receiving antineoplastic therapyAnnals of Oncology, 5
W. Wilson, S. Berg, G. Bryant, R. Wittes, S. Bates, A. Fojo, S. Steinberg, B. Goldspiel, J. Herdt, J. O’Shaughnessy (1994)
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 8
I. Ringel, S. Horwitz (1991)
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.Journal of the National Cancer Institute, 83 4
M. Bissery, G. Nohynek, G. Sanderink, F. Lavelle (1995)
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.Anti-cancer drugs, 6 3
E Trimble, J Adams, D. Vena, M Hawkins, M Friedman, J. Fisherman, M Christian, R. Canetta, N. Onetto, R. Hayn (1993)
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 12
S. Haldar, J. Chintapalli, C. Croce (1996)
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.Cancer research, 56 6
A. Bedikian, G. Weiss, S. Legha, H. Burris, J. Eckardt, J. Jenkins, O. Eton, A. Buzaid, L. Smetzer, D. Hoff (1995)
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
E. Rowinsky, R. Donehower, R. Jones, R. Tucker (1988)
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.Cancer research, 48 14
J. Thigpen, J. Blessing, H. Ball, S. Hummel, R. Barrett (1994)
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 9
E. Rowinsky, E. Eisenhauer, V. Chaudhry, S. Arbuck, R. Donehower (1993)
Clinical toxicities encountered with paclitaxel (Taxol).Seminars in oncology, 20 4 Suppl 3
G. Sarosy, E. Kohn, D. Stone, M. Rothenberg, J. Jacob, D. Adamo, F. Ognibene, R. Cunnion, E. Reed (1992)
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 7
P. Ravdin, H. Burris, Gayle Cook, P. Eisenberg, M. Kane, William Bierman, J. Mortimer, Eric Genevois, R. Bellet (1995)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
J. Hainsworth, D. Thompson, F. Greco (1995)
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 7
W. Murphy, F. Fossella, R. Winn, D. Shin, H. Hynes, H. Gross, Enrique Davilla, J. Leimert, H. Dhingra, M. Raber, I. Krakoff, W. Hong (1993)
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.Journal of the National Cancer Institute, 85 5
Corey Langer, J. Leighton, R. Comis, P. O'Dwyer, C. McAleer, C. Bonjo, Paul Engstrom, Samuel Litwin, R. Ozols (1995)
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 8
V. Knick, D. Eberwein, Charles Miller (1995)
Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.Journal of the National Cancer Institute, 87 14
L. Gianni, E. Munzone, G. Capri, F. Fulfaro, E. Tarenzi, F. Villani, C. Spreafico, A. Laffranchi, A. Caraceni, C. Martini (1995)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 11
A. Dreyfuss, J. Clark, C. Norris, R. Rossi, J. Lucarini, P. Busse, M. Poulin, L. Thornhill, R. Costello, M. Posner (1996)
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
E. Rowinsky, P. Burke, J. Karp, R. Tucker, D. Ettinger, R. Donehower (1989)
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.Cancer research, 49 16
F. Cabral, S. Barlow (1991)
Resistance to antimitotic agents as genetic probes of microtubule structure and function.Pharmacology & therapeutics, 52 2
W. Mcguire, W. Hoskins, W. Hoskins, M. Brady, P. Kucera, E. Partridge, K. Look, D. Clarke‐Pearson, Martin Davidson (1996)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerInternational Journal of Gynecology & Obstetrics, 54
J. Díaz, J. Andreu (1993)
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.Biochemistry, 32 11
M. Jordan, K. Wendell, Sara Gardiner, W. Derry, Hhlary Copp, L. Wilson (1996)
Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.Cancer research, 56 4
Jf Smyth, I. Smith, Cristiana Sessa, Patrick Schöffski, J. Wanders, H. Franklin, Sb Kaye (1994)
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.European journal of cancer, 30A 8
A. Einzig, P. Wiernik, J. Sasloff, C. Runowicz, G. Goldberg (1992)
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 11
E. Eisenhauer, W. Huinink, K. Swenerton, L. Gianni, J. Myles, M. Burg, I. Kerr, J. Vermorken, K. Buser, N. Colombo, M. Bacon, Pedro Santabárbara, N. Onetto, B. Winograd, R. Canetta (1994)
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 12
A. Seidman (1995)
The emerging role of paclitaxel in breast cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 3
Prudence Francis, J. Rigas, J. Rigas, M. Kris, K. Pisters, John Orazem, Karen Woolley, R. Heelan (1994)
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 6
T. Peretz, A. Sulkes, P. Chollet, K. Gelmon, R. Paridaens, V. Gorbonuva, G. Catimel, H. Kuhnle, W. Huinink, D. Khayat, C. Dittrich, U. Klaassen, J. Bergh, N. Wilking, J. Nabholtz, F. Calabresi, M. Tubiana-Hulin, M. Chazard, G. Gallant, K. Diergarten, R. Westberg, J. Bogaert, J. Renard, C. Weil (1995)
345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)European Journal of Cancer, 31
C. Dumontet, G. Duran, K. Steger, L. Beketić-Orešković, B. Sikic (1996)
Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).Cancer research, 56 5
Kearns Cm, L. Gianni, M. Egorin (1995)
Paclitaxel pharmacokinetics and pharmacodynamics.Seminars in oncology, 22 3 Suppl 6
B. Reichman, A. Seidman, J. Crown, R. Heelan, T. Hakes, D. Lebwohl, T. Gilewski, A. Surbone, V. Currie, C. Hudis (1993)
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
A. Chang, Kyungmann Kim, J. Glick, T. Anderson, D. Karp, David Johnson (1993)
Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.Journal of the National Cancer Institute, 85 5
John Kavanagh, A. Kudelka, C. León, D. Tresukosol, M. Hord, M. Finnegan, E. Kim, D. Varma, A. Forman, Paul Cohen, C. Edwards, R. Freedman, C. Verschraegen (1996)
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 5
B. Chevallier, P. Fumoleau, P. Kerbrat, V. Diéras, H. Roché, I. Krakowski, N. Azli, M. Bayssas, M. Lentz, M. Glabbeke (1995)
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 2
M. Trudeau, E. Eisenhauer, B. Higgins, F. Letendre, W. Lofters, B. Norris, T. Vandenberg, F. Delorme, A. Muldal (1996)
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 2
M. Kennedy, M. Zahurak, R. Donehower, D. Noe, S. Sartorius, T. Chen, K. Bowling, E. Rowinsky (1996)
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
F. Fossella, Jangsoon Lee, D. Shin, Maria Calayag, M. Huber, R. Perez-soler, W. Murphy, S. Lippman, Benner Se, B. Glisson (1995)
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 3
L. Webster, Martha Linsenmeyer, M. Millward, C. Morton, J. Bishop, D. Woodcock (1993)
Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.Journal of the National Cancer Institute, 85 20
H. Kunitoh, Koshiro Watanabe, T. Onoshi, K. Furuse, H. Niitani, Tetsuo Taguchi (1996)
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
S. Horwitz, D. Cohen, Srinivasa Rao, Israel Ringel, Shen Hj, Yang Cp (1986)
Taxol: Mechanisms of Action and Resistance aAnnals of the New York Academy of Sciences, 466
Q. Hoesel, J. Verweij, G. Catimel, M. Clavel, P. Kerbrat, A. Oosterom, J. Kerger, T. Tursz, M. Glabbeke, C. Pottelsberghe, N. Bail, H. Mouridsen (1994)
Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adultAnnals of Oncology, 5
E. Rowinsky, W. McGuire, T. Guarnieri, J. Fisherman, M. Christian, R. Donehower (1991)
Cardiac disturbances during the administration of taxol.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 9
A. Oosterom, Dirk Schriivers (1995)
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.Anti-Cancer Drugs, 6
Bruce Roth, R. Dreicer, Lawrence Einhorn, Donna Neuberg, David Johnson, Julia Smith, G. Hudes, S. Schultz, P. Loehrer (1994)
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 11
M. Glantz, H. Choy, C. Kearns, B. Cole, P. Mills, E. Zuhowski, S. Saris, C. Rhodes, E. Stopa, M. Egorin (1996)
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 2
H. Choy, W. Akerley, H. Safran, Jeffrey Clark, V. Rege, A. Papa, M. Glantz, Y. Puthawala, C. Soderberg, L. Leone (1994)
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 12
W. Wilson, B. Chabner, G. Bryant, S. Bates, A. Fojo, J. Regis, E. Jaffe, S. Steinberg, B. Goldspiel, B. Cheson (1995)
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 2
D. Kerr (1994)
Phase I clinical trials: adapting methodology to face new challenges.Annals of oncology : official journal of the European Society for Medical Oncology, 5 Suppl 4
S. Aamdal, I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, Jacob Schachter, J. Wanders, H. Franklin, J. Verweij (1994)
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.European journal of cancer, 30A 8
A. Sulkes, J. Smyth, C. Sessa, LY Dirix, J. Vermorken, S. Kaye, J. Wanders, H. Franklin, N. Lebail, J. Verweij, for Group (1994)
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.British Journal of Cancer, 70
G. Capri, E. Munzone, E. Tarenzi, F. Fulfaro, L. Gianni, A. Caraceni, C. Martini, V. Scaioli (1994)
Optic nerve disturbances: a new form of paclitaxel neurotoxicity.Journal of the National Cancer Institute, 86 14
V. Chaudhry, E. Rowinsky, S. Sartorius, R. Donehower, D. Cornblath (1994)
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studiesAnnals of Neurology, 35
E. Rowinsky, E. Rowinsky, Nicole Onetto, Nicole Onetto, Renzo Canetta, Renzo Canetta, Susan Arbuck, Susan Arbuck (1992)
Taxol: the first of the taxanes, an important new class of antitumor agents.Seminars in oncology, 19 6
SRINIVASA Rao, N. Krauss, J. Heerding, C. Swindell, I. Ringel, G. Orr, S. Horwitz (1994)
3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin.The Journal of biological chemistry, 269 5
M. Piccart, M. Gore, W. Huinink, A. Oosterom, J. Verweij, J. Wanders, Hilary Frankli, M. Bayssas, S. Kaye (1995)
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.Journal of the National Cancer Institute, 87 9
A. Seidman, B. Reichman, J. Crown, T. Yao, V. Currie, T. Hakes, C. Hudis, T. Gilewski, J. Baselga, P. Forsythe (1995)
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 5
F. Holmes, R. Walters, R. Theriault, A. Buzdar, D. Frye, G. Hortobagyi, A. Forman, L. Newton, M. Raber (1991)
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.Journal of the National Cancer Institute, 83 24
L. Gianni, Kearns Cm, A. Giani, G. Capri, L. Viganò, A. Lacatelli, G. Bonadonna, M. Egorin (1995)
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 1
W. Mcguire, E. Rowinsky, N. Rosenshein, F. Grumbine, D. Ettinger, D. Armstrong, R. Donehower (1989)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.Annals of Internal Medicine, 111
A. Seidman, A. Tiersten, C. Hudis, M. Gollub, S. Barrett, T. Yao, J. Lepore, T. Gilewski, V. Currie, J. Crown (1995)
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 10
R. Wit, M. Burg, A. Gaast, A. Logmans, G. Stoter, J. Verweij (1994)
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 5 7
E. Rowinsky, R. Donehower (1995)
Drug therapy : paclitaxel (Taxol)The New England Journal of Medicine, 332
W. Huinink, A. Prové, M. Piccart, W. Steward, T. Tursz, J. Wanders, H. Franklin, M. Clavel, J. Verweij, M. Alakl, M. Bayssas, S. Kaye (1994)
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.Annals of oncology : official journal of the European Society for Medical Oncology, 5 6
A. Younes, A. Sarris, A. Melnyk, J. Romaguera, P. Mclaughlin, F. Swan, M. Rodriguez, F. Hagemeister, D. Moore, L. North (1995)
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 3
W. Mcguire, J. Blessing, D. Moore, S. Lentz, G. Photopulos (1996)
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
L. Gianni, E. Munzone, G. Capri, F. Villani, C. Spreafico, E. Tarenzi, F. Fulfaro, A. Caraceni, C. Martini, A. Laffranchi, P. Valagussa, G. Bonadonna (1995)
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.Journal of the National Cancer Institute, 87 15
T. Cerny, S. Kaplan, N. Pavlidis, P. Schöffski, R. Epelbaum, J. Meerbeek, J. Wanders, H. Franklin, S. Kaye, for Ectg (1994)
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)British Journal of Cancer, 70
V. Valero, F. Holmes, R. Walters, R. Theriault, L. Esparza, G. Fraschini, G. Fonseca, R. Bellet, A. Buzdar, G. Hortobagyi (1995)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
J. Ajani, D. Ilson, K. Daugherty, R. Pazdur, P. Lynch, D. Kelsen (1994)
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.Journal of the National Cancer Institute, 86 14
G. Catimel, J. Verweij, V. Mattijssen, A. Hanauske, M. Piccart, J. Wanders, H. Franklin, N. Bail, M. Clavel, S. Kaye (1994)
Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neckAnnals of Oncology, 5
F. Fossella, J. Lee, W. Murphy, S. Lippman, Maria Calayag, A. Pang, Marvin Chasen, D. Shin, B. Glisson, S. Benner, M. Huber, Roman Perez-Soler, W. Hong, M. Raber (1994)
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 6
Elise Kohn, G. Sarosy, A. Bicher, Charles Link, M Christian, S. Steinberg, M. Rothenberg, D. Adamo, P. Davis, F. Ognibene, Robert Cunnion, Eddie Reed (1994)
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.Journal of the National Cancer Institute, 86 1
Prudence Francis, J. Schneider, L. Hann, C. Balmaceda, Richard Barakat, M. Phillips, T. Hakes (1994)
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 11
J. Manfredi, S. Horwitz (1984)
Taxol: an antimitotic agent with a new mechanism of action.Pharmacology & therapeutics, 25 1
Françoise Marre, Ger-Jan Sanderink, G. Sousa, Franã oisemarre, Claude Gaillard, Michel Martinet, Roger Rahmani (1996)
Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.Cancer research, 56 6
A. Forastiere, D. Neuberg, S. Taylor, R. Deconti, G. Adams (1993)
Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial.Journal of the National Cancer Institute. Monographs, 15
G. Hudes, C. Obasaju, A. Chapman, J. Gallo, C. McAleer, R. Greenberg (1995)
Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.Seminars in oncology, 22 3 Suppl 6
R. Weiss, R. Donehower, P. Wiernik, T. Ohnuma, R. Gralla, D. Trump, J. Baker, D. Echo, D. Hoff, B. Leyland-Jones (1990)
Hypersensitivity reactions from taxol.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 7
▪ Abstract The taxane class of antimicrotubule anticancer agents is perhaps the most important addition to the chemotherapeutic armamentarium against cancer over the past several decades. After only a brief period, the taxanes have not only demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head and neck, bladder, and esophagus, they have also demonstrated effectiveness in the initial therapy of earlier stages of cancer, a setting in which any new therapy is likely to make its greatest impact. The challenge now facing investigators is to develop strategies to maximize therapeutic benefits with the taxanes in the early stages, as well as the advanced stages, of many cancers. This review describes the preclinical features and clinical results of the two major taxanes, paclitaxel (Taxol®, Bristol-Myers Squibb) and docetaxel (Taxotere®, Rhone-Poulenc Rhorer).
Annual Review of Medicine – Annual Reviews
Published: Feb 1, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.